We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG V”), a $615 million fund focused on early-stage investments, and The Column Group Opportunity III (“TCG Opportunity III”), also $615 million but focused on later stage investments in our companies.
With TCG V, the firm will continue to execute on the strategy we have deployed since inception – assembling a focused portfolio of “big idea” companies, believed to be led by some of the most talented scientists in the world, each built from the ground up with platforms seemingly capable of generating multiple differentiated product opportunities.
With the addition of TCG Opportunity III, we will have substantial capital to also support our companies in their later stages of progress through clinical trials and patient dosing. We see the coming 12-24 months as a challenging but exciting period where well capitalized venture funds can be able to support their best portfolio companies and likely outperform venture funds with more restricted capital. TCG will have an opportunity to “double-down” and increase our ownership in our best and most promising companies.
TCG has raised $3.5 billion and started or invested in 41 companies from inception to date. Since the founding of the firm in 2007, TCG has viewed early-stage drug discovery investing as a compelling path to value creation through the advancement of new, highly effective human therapies that can change the world. We believe that focus is critical, and we will continue to deploy a hands-on approach to building a small cohort of high quality, science-driven companies.
Looking back on our portfolio, while we are proud that we have been successful in generating notable performing investment returns in our funds, we are even more proud that we have been able to build impactful companies that are bringing life-changing drugs to patients. Peloton, which was sold to Merck, developed “WELIREG” to treat adults with cancers associated with VHL disease, a serious disorder that causes tumors and cysts to grow in certain areas of the body such as the brain, spinal cord, eyes, inner ear, adrenal glands, kidney, pancreas, and reproductive tract. Peloton’s drug was the first-ever drug approved by the FDA to treat VHL disease. Similarly, Aragon, which was sold to J&J, developed “ERLEADA”, a prostate cancer drug that has been approved for use worldwide. While other drugs in our portfolio are still in various clinical stages, we are hopeful that these too will prove to be disease game changers following the paths of WELIREG and ERLEADA.
We thank you for your continued support and look forward to continuing our close and successful partnership over the years to come!
About The Column Group
The Column Group is a leading venture capital firm based in San Francisco that seeks to partner with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in disease-focused drug discovery companies with the potential to become leaders in their respective fields. These companies are strongly supported by the unique and complementary skill sets of TCG’s team, which includes prominent authorities in the scientific, operational, and financial arenas.
For more information, please visit www.thecolumngroup.com.
Past performance is not indicative of future results, there is no guarantee that current or future funds will achieve comparable results. This release is presented for informational purposes only and should not be construed as investment advice. It is not a recommendation or, or an offer to sell or solicitation of an offer to buy interests into any fund. Our views and opinions expressed herein are current at the time of publication and are subject to change.
